Alice Hervieu

879 total citations
31 papers, 395 citations indexed

About

Alice Hervieu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Alice Hervieu has authored 31 papers receiving a total of 395 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 5 papers in Immunology. Recurrent topics in Alice Hervieu's work include Colorectal Cancer Treatments and Studies (11 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Sarcoma Diagnosis and Treatment (6 papers). Alice Hervieu is often cited by papers focused on Colorectal Cancer Treatments and Studies (11 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Sarcoma Diagnosis and Treatment (6 papers). Alice Hervieu collaborates with scholars based in France, United States and Germany. Alice Hervieu's co-authors include François Ghiringhelli, Nicolás Isambert, Grégoire Mignot, Cédric Rébé, Aurélie Bertaut, Audrey Hennequin, Sylvie Zanetta, Lionel Apétoh, P. Vabres and Frédérique Végran and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

Alice Hervieu

31 papers receiving 391 citations

Peers

Countries citing papers authored by Alice Hervieu

Since Specialization

Citations

This map shows the geographic impact of Alice Hervieu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alice Hervieu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alice Hervieu more than expected).

Fields of papers citing papers by Alice Hervieu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alice Hervieu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alice Hervieu. The network helps show where Alice Hervieu may publish in the future.

Co-authorship network of co-authors of Alice Hervieu

This figure shows the co-authorship network connecting the top 25 collaborators of Alice Hervieu. A scholar is included among the top collaborators of Alice Hervieu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alice Hervieu. Alice Hervieu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	FOLFIRINOX-3 plus bevacizumab (bFOLFIRINOX3) in chemo-refractory metastatic colorectal cancer: a multicenter phase II trial 2025 ·Future Oncology ·(unknown), (unknown), Aurélie Bertaut, Alice Hervieu, Sylvie Zanetta, (unknown), Julie Vincent, Leila Bengrine, Audrey Hennequin, (unknown), (unknown), (unknown), François Ghiringhelli, Jean-David Fumet	3
2	Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study 2025 ·Journal for ImmunoTherapy of Cancer ·Jean‐Sébastien Frenel, (unknown), Claire Cropet, Édith Borcoman, Alice Hervieu, Elodie Coquan, Thibault De La Motte Rouge, Esma Saâda-Bouzid, Renaud Sabatier, Pernelle Lavaud, Marta Jimenez, (unknown), Olivia Le Saux, Emmanuelle Charafe‐Jauffret, Anthony Gonçalvès	1
3	Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study 2025 ·The Breast ·(unknown), Jean‐Sébastien Frenel, (unknown), Édith Borcoman, Alice Hervieu, George Emile, (unknown), (unknown), (unknown), Emilie Dassé, (unknown)	1
4	LBA79 LENVAGIST: A multicentre, comparative, placebo (P)-controlled, double-blinded, phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib 2024 ·Annals of Oncology ·Axel Le Cesne, Claire Cropet, Mehdi Brahmi, Rastislav Bahleda, Emmanuelle Bompas, (unknown), Alice Hervieu, Olivier Bouché, Armelle Dufresne, (unknown), Kévin Bourcier, Florence Duffaud, Marc Pracht, François Bertucci, Loïc Lebellec, Antoîne Italiano, Clémence Henon, Julien Gautier, David Pérol, Jean‐Yves Blay	1
5	Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study 2023 ·ESMO Open ·Axel Le Cesne, Christine Chevreau, Christophe Perrin, Antoîne Italiano, Alice Hervieu, Jean‐Yves Blay, Sophie Piperno‐Neumann, Esma Saâda-Bouzid, François Bertucci, Nelly Firmin, Elsa Kalbacher, (unknown), Camille Schiffler, (unknown), Marta Jimenez, Corinne Bouvier, Vincent Vidal, Sylvie Chabaud, Florence Duffaud	9
6	Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol 2023 ·BMC Cancer ·Lionnel Geoffrois, Alexandre Harlé, (unknown), (unknown), F. Granel‐Brocard, Alice Hervieu, Laurent Mortier, G. Jeudy, Catherine Michel, Charlée Nardin, Cècile Huin‐Schohn, Jean‐Louis Merlin	3
7	1927P Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years 2023 ·Annals of Oncology ·Axel Le Cesne, Jean‐Yves Blay, Sophie Piperno‐Neumann, Sarah Watson, Armelle Dufresne, Thibaud Valentin, Florence Duffaud, Maud Toulmonde, Antoîne Italiano, François Bertucci, Camille Tlemsani, Nelly Firmin, Emmanuelle Bompas, Christophe Perrin, Esma Saâda, Pascale Dubray‐Longeras, Alice Hervieu, Françoise Ducimetière, Mehdi Brahmi, Nicolas Penel	1
8	1928P Differential presentation and outcome of sclerosing epithelioid fibrosarcoma (SEF) vs low grade fibromyxoid sarcoma (LGFMS): The nationwide series of 330 patients in NETSARC since 2010 2023 ·Annals of Oncology ·Jean‐Yves Blay, (unknown), Maud Toulmonde, Antoîne Italiano, Nicolas Penel, (unknown), F. Gouin, Thibaud Valentin, Florence Duffaud, Louis‐Romée Le Nail, Sarah Watson, Nelly Firmin, Pascale Dubray‐Longeras, M. Ropars, Alice Hervieu, F. Fiorenza, Célèste Lebbé, Esma Saâda, (unknown), Axel Le Cesne	3
9	1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial 2023 ·Annals of Oncology ·Benjamin Solomon, Alexander Drilon, W. Marston Linehan, Lyudmila Bazhenova, Keiko Goto, J. De Langen, Dongwook Kim, Jennifer Moriatis Wolf, Christoph Springfeld, Sanjay Popat, Wan‐Teck Lim, Christina S. Baik, Alice Hervieu, Víctor Moreno, Nong Yang, (unknown), Felipe Ades, (unknown), Benjamin Besse	26
10	478P Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D): Results of the tumor mutational burden-high (TMB-h) and/or microsatellite instability-high (MSI-h) cohort of the MOVIE study 2022 ·Annals of Oncology ·Alice Hervieu, J. Guigay, Édith Borcoman, Pernelle Lavaud, Elodie Coquan, Jean‐Sébastien Frenel, Thibault De La Motte Rouge, (unknown), Claire Cropet, (unknown), A. Gonçalves	4
11	Phase I dose-escalation study of desynchronized irinotecan plus bevacizumab, oxaliplatin, 5-fluorouracil, and folinic acid (bFOLFIRINOX-3) administration in chemorefractory metastatic colorectal cancer patients. 2021 ·Journal of Clinical Oncology ·Jean-David Fumet, Alice Hervieu, Audrey Hennequin, Sylvie Zanetta, Aurélie Bertaut, François Ghiringhelli	1
12	Abstract P02-01: Repotrectinib in patients with NTRK fusion-positive advanced solid tumors: update from the registrational phase 2 TRIDENT-1 trial 2021 ·Molecular Cancer Therapeutics ·Benjamin Besse, Christina S. Baik, Christoph Springfeld, Alice Hervieu, Víctor Moreno, Lyudmila Bazhenova, W. Marston Linehan, D. Ross Camidge, Benjamin Solomon, Vamsidhar Velcheti, Anthonie J. van der Wekken, Enriqueta Felip, Dipesh Uprety, Denise Trone, Shanna Stopatschinskaja, Byoung Chul Cho, Alexander Drilon	4
13	Limbs and trunk soft tissue sarcoma systematic local and remote monitoring by MRI and thoraco-abdomino-pelvic scanner: A single-centre retrospective study 2019 ·European Journal of Surgical Oncology ·(unknown), (unknown), Aurélie Bertaut, N. Méjean, (unknown), Alice Hervieu, G. Truc, (unknown), (unknown), J. Fraisse, (unknown), Nicolás Isambert, Sylvain Causeret	6
14	Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer 2018 ·ESMO Open ·Jean David Fumet, Nicolás Isambert, Alice Hervieu, Sylvie Zanetta, (unknown), Audrey Hennequin, (unknown), Aurélie Bertaut, François Ghiringhelli	41
15	PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer 2017 ·European Journal of Cancer ·Mathilde Guérin, Keyvan Rezaï, Nicolás Isambert, Mario Campone, A Autret, Jihane Pakradouni, Magali Provansal, Jacques Camerlo, Renaud Sabatier, François Bertucci, Emmanuelle Charafe‐Jauffret, Alice Hervieu, Jean-Marc Extra, Patrice Viens, François Lokiec, Jean‐Marie Boher, Anthony Gonçalvès	45
16	A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification 2017 ·European Journal of Cancer ·Eric Angevin, Gianluca Spitaleri, Jordi Rodón, Katia Dotti, Nicolás Isambert, Stefania Salvagni, Víctor Moreno, Sylvie Assadourian, (unknown), (unknown), Antoine Hollebecque, Analía Azaro, Alice Hervieu, Karim Rihawi, Filippo de Marinis	35
17	Abstract A118: PIKHER2: A phase Ib study evaluating oral BKM120 in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer 2015 ·Molecular Cancer Therapeutics ·Anthony Gonçalvès, Mathilde Guérin, Nicolás Isambert, Mario Campone, (unknown), A Autret, Jihane Pakradouni, (unknown), Magali Provansal, Emmanuelle Charafe‐Jauffret, Renaud Sabatier, Alice Hervieu, Jean-Marc Extra, Patrice Viens, François Lokiec, Jean‐Marie Boher	3
18	Prospective Study of the Evolution of Blood Lymphoid Immune Parameters during Dacarbazine Chemotherapy in Metastatic and Locally Advanced Melanoma Patients 2014 ·PLoS ONE ·Grégoire Mignot, Alice Hervieu, P. Vabres, S. Dalac, G. Jeudy, (unknown), Lionel Apétoh, François Ghiringhelli	11
19	Dacarbazine mediates antimelanoma effects via NK cells 2013 ·OncoImmunology ·Alice Hervieu, Grégoire Mignot, François Ghiringhelli	15
20	Dacarbazine-Mediated Upregulation of NKG2D Ligands on Tumor Cells Activates NK and CD8 T Cells and Restrains Melanoma Growth 2012 ·Journal of Investigative Dermatology ·Alice Hervieu, Cédric Rébé, Frédérique Végran, Fanny Chalmin, Mélanie Bruchard, P. Vabres, Lionel Apétoh, François Ghiringhelli, Grégoire Mignot	77

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact